TY - JOUR
T1 - Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection
AU - Micic, Dejan
AU - Rao, Krishna
AU - Trindade, Bruno Caetano
AU - Walk, Seth T.
AU - Chenoweth, Elizabeth
AU - Jain, Ruchika
AU - Trivedi, Itishree
AU - Santhosh, Kavitha
AU - Young, Vincent B.
AU - Aronoff, David M.
N1 - Publisher Copyright:
© D. Micic et al., 2015.
PY - 2015
Y1 - 2015
N2 - Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.
AB - Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.
KW - Biomarkers
KW - Clostridium difficile
KW - Colitis
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=84946023003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946023003&partnerID=8YFLogxK
U2 - 10.4081/idr.2015.5979
DO - 10.4081/idr.2015.5979
M3 - Article
AN - SCOPUS:84946023003
SN - 2036-7430
VL - 7
SP - 50
EP - 55
JO - Infectious Disease Reports
JF - Infectious Disease Reports
IS - 3
ER -